Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11922MR)

This product GTTS-WQ11922MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11922MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8739MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ8548MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ3674MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ3304MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ7818MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ12446MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ3366MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ907MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW